IN THE CLAIMS

Please amend the claims as follows:

Claims 1-23 (Cancelled)

Claim 24 (New): A method for predicting a drug transport capability of a mammalian cell, comprising:

determining whether a mammalian cell has a polymorphism at position 421 of the ABCG2 gene of SEQ ID NO: 1, or

determining whether an ABCG2 polypeptide produced by said mammalian cell has an amino acid substitution at position 141 of SEO ID NO: 2:

wherein the presence of a polynucleotide polymorphism at position 421 an amino acid substitution at position 141 is indicative of altered drug transport capability of said mammalian cell.

Claim 25 (New): The method of Claim 24, wherein the presence of a polynucleotide polymorphism at position 421 an amino acid substitution at position 141 is indicative of altered drug transport capability of said mammalian cell for an indolocarbazole compound of formula (I):

wherein X^1 and X^2 each independently represent a hydrogen atom, halogen atom or hydroxyl group,

R represents a hydrogen atom, amino, formylamino, or lower alkylamino wherein said lower alkylamino may be substituted with any one selected from the group consisting of one to three hydroxyl, a pyridyl optionally having substituent(s), and a thienyl optionally having substituent(s), and

G represents a pentose group or hexose group or derivative thereof which may be substituted with an amino group

Claim 26 (New): The method of Claim 24, wherein the presence of a polynucleotide polymorphism at position 421 or an amino acid substitution at position 141 is indicative of altered drug transport capability of said mammalian cell for Compound A.

Claim 27 (New): The method of Claim 24, wherein the presence of a polynucleotide polymorphism at position 421 or an amino acid substitution at position 141 is indicative of altered drug transport capability of said mammalian cell for Compound B.

Claim 28 (New): The method of Claim 24, wherein said mammalian cell is a human cell

Claim 29 (New): The method of Claim 24, wherein the mammalian cell is derived from a patient suffering from cancer.

Claim 30 (New): The method of Claim 24, further comprising collecting a mammalian cell sample from body fluid, skin, hair root, mucous membrane, internal organ, placenta, or cord blood of a subject prior to said determining step.

Claim 31 (New): The method of Claim 24, which comprises detecting a polymorphism by a direct sequencing method.

Claim 32 (New): The method of Claim 24, which comprises detecting a polymorphism by a Taqman method.

Claim 33 (New): The method of Claim 24, which comprises detecting a polymorphism by an invader method.

Claim 34 (New): The method of Claim 24, which comprises detecting a polymorphism by a mass spectrometric method, RCA method or DNA chip method.

Claim 35 (New): The method of Claim 24, which comprises detecting the C421A polymorphism.

Claim 36 (New): The method of Claim 24, which comprises detecting the amino acid substitution at position 141 by a mass spectrometric method, a two-dimensional electrophoresis method, or a protein chip method.

Claim 37 (New): The method of Claim 24, wherein the presence of a polynucleotide polymorphism at position 421 or an amino acid substitution at position 141 is indicative of decreased drug transport capability of said mammalian cell.

Claim 38 (New): The method of Claim 24, which comprises detecting the Gln141Lys substitution in a polypeptide produced by the mammalian cell.

Claim 39 (New): The method of Claim 24, further comprising

determining whether a mammalian cell has at least one other polymorphism in the ABCG2 gene of SEQ ID NO: 1, or

determining whether an ABCG2 polypeptide produced by said mammalian cell has at least one other amino acid substitution of SEO ID NO: 2.

Claim 40 (New): The method of Claim 39, wherein said at least one other polymorphism is at position 34.

Claim 41 (New): The method of Claim 39, wherein said at least one other polymorphism is at position 376.

Claim 42 (New): The method of Claim 39, wherein said at least one other amino acid substitution is at position 12.

Application No. 10/517,310 Reply to Office Action of November 30, 2006

Claim 43 (New): The method of Claim 39, wherein said at least one other amino acid substitution is at position 126.